快速进展性痴呆患者脑脊液生物标志物的诊断效用
研究纳入78例快速进展性痴呆(RPD)患者、35例年龄性别匹配的典型进展性神经退行性疾病患者和72例认知正常对照,检测脑脊液中的阿尔茨海默病、神经轴索损伤、神经炎症和突触功能障碍生物标志物。结果显示,阿尔茨海默病生物标志物与神经退行性病因相关,高NfL、sTREM2、YKL-40和低VILIP-1识别自身免疫/炎症性疾病,MCP-1在血管性病因中最高。包含GFAP、MCP-1、p-tau181和sTREM2的多变量模型以89%的准确率识别44例治疗反应性病因患者。
要点
- 脑脊液阿尔茨海默病生物标志物与RPD神经退行性病因相关。
- 高NfL、sTREM2、YKL-40和低VILIP-1提示自身免疫/炎症性病因。
- GFAP、MCP-1、p-tau181和sTREM2模型识别治疗反应性病因准确率89%。
核心结论
- 就诊时选定的脑脊液生物标志物与RPD患者病因诊断和治疗反应性相关。
- 横断面生物标志物反映快速进展性神经退行性疾病驱动机制的能力尚不明确。
研究设计与样本
- 前瞻性纳入78例因神经退行性、血管性和自身免疫/炎症性疾病导致的RPD患者。
- 纳入35例年龄和性别匹配的典型进展性神经退行性疾病患者和72例认知正常对照。
- 检测就诊时脑脊液中的阿尔茨海默病、神经轴索/神经元损伤、神经炎症和突触功能障碍生物标志物。
主要发现
- 阿尔茨海默病生物标志物与RPD的神经退行性病因相关。
- 高NfL、sTREM2、YKL-40和低VILIP-1识别自身免疫/炎症性疾病患者。
- MCP-1水平在血管性病因RPD患者中最高。
- 包含GFAP、MCP-1、p-tau181和sTREM2的多变量模型以89%准确率识别44例治疗反应性病因患者。
- 典型与快速进展性神经退行性疾病表现之间差异极小。
关键数值与推荐
- 多变量模型(GFAP、MCP-1、p-tau181、sTREM2)识别治疗反应性RPD的准确率为89%。
临床怎么用
- 就诊时选定的脑脊液生物标志物与RPD病因诊断和治疗反应性相关。
局限性
- 横断面生物标志物反映快速进展性神经退行性疾病驱动机制的能力尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study was undertaken to apply established and emerging cerebrospinal fluid (CSF) biomarkers to improve diagnostic accuracy in patients with rapidly progressive dementia (RPD). Overlap in clinical presentation and results of diagnostic tests confounds etiologic diagnosis in patients with RPD. Objective measures are needed to improve diagnostic accuracy and to recognize patients with potentially treatment-responsive causes of RPD. METHODS: Biomarkers of Alzheimer disease neuropathology (amyloid-β 42/40 ratio, phosphorylated tau [p-tau181, p-tau231]), neuroaxonal/neuronal injury (neurofilament light chain [NfL], visinin-like protein-1 [VILIP-1], total tau), neuroinflammation (chitinase-3-like protein [YKL-40], soluble triggering receptor expressed on myeloid cells 2 [sTREM2], glial fibrillary acidic protein [GFAP], monocyte chemoattractant protein-1 [MCP-1]), and synaptic dysfunction (synaptosomal-associated protein 25kDa, neurogranin) were measured in CSF obtained at presentation from 78 prospectively accrued patients with RPD due to neurodegenerative, vascular, and autoimmune/inflammatory diseases; 35 age- and sex-matched patients with typically progressive neurodegenerative disease; and 72 cognitively normal controls. Biomarker levels were compared across etiologic diagnoses, by potential treatment responsiveness, and between patients with typical and rapidly progressive presentations of neurodegenerative disease. RESULTS: Alzheimer disease biomarkers were associated with neurodegenerative causes of RPD. High NfL, sTREM2, and YKL-40 and low VILIP-1 identified patients with autoimmune/inflammatory diseases. MCP-1 levels were highest in patients with vascular causes of RPD. A multivariate model including GFAP, MCP-1, p-tau181, and sTREM2 identified the 44 patients with treatment-responsive causes of RPD with 89% accuracy. Minimal differences were observed between typical and rapidly progressive presentations of neurodegenerative disease. INTERPRETATION: Selected CSF biomarkers at presentation were associated with etiologic diagnoses and treatment responsiveness in patients with heterogeneous causes of RPD. The ability of cross-sectional biomarkers to inform upon mechanisms that drive rapidly progressive neurodegenerative disease is less clear. ANN NEUROL 2024;95:299-313.
引用
- Kuchenbecker LA, Tipton PW, Martens Y, et al. Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia. Ann Neurol. 2023. PMID: 37897306. doi:10.1002/ana.26822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。